Navigation Links
Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Date:5/30/2008

as.

Welchol is contraindicated in individuals with bowel obstruction, those with serum triglyceride (TG) concentrations of >500 mg/dL, or with a history of hypertriglyceridemia-induced pancreatitis.

The effect of Welchol on cardiovascular morbidity and mortality has not been determined. Welchol can increase serum TG concentrations particularly when used in combination with sulfonylureas or insulin. Caution should be exercised when treating patients with TG levels >300 mg/dL.

Welchol may decrease the absorption of fat-soluble vitamins A, D, E, and K. Patients on vitamin supplements should take their vitamins at least 4 hours prior to Welchol. Caution should be exercised when treating patients with a susceptibility to vitamin K or fat soluble vitamin deficiencies.

Caution should also be exercised when treating patients with gastroparesis, gastrointestinal motility disorders, major gastrointestinal tract surgery, and when treating patients with dysphagia and swallowing disorders.

Welchol reduces gastrointestinal absorption of some drugs. Drugs with a known interaction with colesevelam (glyburide, levothyroxine, and oral contraceptives [ethinyl estradiol, norethindrone]) should be administered at least 4 hours prior to Welchol. Drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index, should also be administered at least 4 hours prior to Welchol. Alternatively, the physician should monitor drug levels of the co-administered drug.

Primary Hyperlipidemia: In clinical trials, the adverse reactions observed in greater than or equal to 2% of patients - and more commonly with Welchol than placebo -- regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% vs. 3.1%), rhinitis (3.2% vs. 3.1%)
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
3. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
4. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
7. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
8. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
11. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... MANALAPAN, N.J. , May 22, 2013 ... this opportunity to update shareholders about some recent company ... will expand its avenues of communication with shareholders. Integrating ... has launched a Facebook page and will post updates ... the Twitter hashtag is #medifirstusa. Says ...
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
Breaking Medicine Technology:MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Medifirst Solutions, Inc. Announces Update To Shareholders 2Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... board, The J. M. Smucker Company, and Danny ... Awards yesterday at the GS1 General Assembly and Global ... Mr. Smucker and Mr. Wegman were recognized for their ... Standards - the most broadly used supply chain standards ...
(Date:5/22/2013)... report these findings in the current online edition ... pan-European study could open up new possibilities of ... which tackle diseases before the patient,s nervous system ... group of genetic diseases of the cerebellum and ... have limited control of their muscles. They also ...
(Date:5/22/2013)... new guidelines the first in more than 35 ... for surgical patients. The recommendations, based on a lengthy ... (JHH), can potentially save the medical center more than ... , A report on the research that led up ... Anesthesiology , suggests millions of dollars a year ...
(Date:5/22/2013)... Toppik and Bosley hair fibers, two hair loss concealer products ... hair. Hair loss treatments can be a lengthy process. In ... waiting period, one can use these hair loss concealers. They ... surgery in general. , Bosley and Toppik Hair Thickening ... eliminate the appearance of balding and thinning hair. It is ...
(Date:5/22/2013)... NC (PRWEB) May 22, 2013 The 2013 ... (DSM-5) is the largest change to hit the field ... Jung Center is will help prepare for the release with ... therapists has been trained knowing no other diagnostic scheme besides ... DSM-5 diagnostic manual will be released worldwide. In honor of ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Johns Hopkins rewrites obsolete blood-ordering rules 2Health News:Johns Hopkins rewrites obsolete blood-ordering rules 3Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2
... Conferring with pharmacists permits quicker changes in drugs, improved ... -- Monitoring your blood pressure at home and reporting ... keep blood pressure readings lower than standard care does, ... half of people who used this system of blood ...
... AUSTIN, TexasMechanical engineering Assistant Professor Adela Ben-Yakar at The ... "microscalpel" that destroys a single cell while leaving nearby ... for cancer, epilepsy and other diseases. , "You can ... damaging the cells above and below it," Ben-Yakar says. ...
... Brava, LLC announces a major milestone.,Since its introduction 7 ... have used the Brava Breast Enhancement System. The Brava,system ... from,Brava in the United States and through international distributors ... V. Freyre, President and CEO of Brava, "We are ...
... Cycle Would Create a ,Stampede, of Other ... WASHINGTON, June 24 As policymakers ... package, they face the decision of,either supporting ... postponing the Average Manufacturer Price (AMP) pharmacy ...
... WASHINGTON, June 24 The American Lung,Association commends ... its,passage of the Pulmonary and Cardiac Rehabilitation Act ... Patients and Providers Act of,2008, the Pulmonary and ... make life easier for millions of Americans who ...
... who goes for tests, study concludes , , TUESDAY, ... from colorectal cancer among minorities in United States may ... cultural barriers that lead to less preventative screening among ... The report, published in the June 23 issue of ...
Cached Medicine News:Health News:Going Online to Draw the Line on High Blood Pressure 2Health News:Going Online to Draw the Line on High Blood Pressure 3Health News:Laser surgery probe targets individual cancer cells 2Health News:Time for Policymakers to Choose: 'Prompt Pay' Mandate or Postpone AMP Reimbursement Cuts 2Health News:American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act 2Health News:Social, Health Care Factors Drive Colon Screen Disparities 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: